Park National Corp OH Grows Holdings in Allergan PLC. (AGN)

Park National Corp OH boosted its holdings in shares of Allergan PLC. (NYSE:AGN) by 11.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,810 shares of the company’s stock after buying an additional 4,011 shares during the quarter. Park National Corp OH’s holdings in Allergan PLC. were worth $7,954,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in AGN. Veritas Asset Management LLP acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $761,339,000. Iridian Asset Management LLC CT increased its position in shares of Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after purchasing an additional 751,848 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Allergan PLC. in the 1st quarter valued at approximately $124,255,000. Vanguard Group Inc. increased its position in shares of Allergan PLC. by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after purchasing an additional 482,220 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. increased its position in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after purchasing an additional 370,400 shares during the last quarter. Institutional investors own 81.94% of the company’s stock.

A number of brokerages have commented on AGN. Royal Bank Of Canada reissued an “outperform” rating and issued a $250.00 price objective (down from $277.00) on shares of Allergan PLC. in a research report on Thursday. They noted that the move was a valuation call. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research report on Monday, June 26th. BidaskClub downgraded shares of Allergan PLC. from a “sell” rating to a “strong sell” rating in a research report on Friday, August 25th. Mizuho reissued a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a research report on Monday, September 25th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $258.00 price objective on shares of Allergan PLC. in a research report on Wednesday. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $252.39.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.52% during mid-day trading on Friday, reaching $188.28. 4,755,555 shares of the company were exchanged. Allergan PLC. has a 12 month low of $182.80 and a 12 month high of $256.80. The company’s 50-day moving average is $211.30 and its 200 day moving average is $230.36. The firm has a market capitalization of $62.94 billion, a price-to-earnings ratio of 5.74 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts predict that Allergan PLC. will post $16.21 EPS for the current year.

Allergan PLC. announced that its board has authorized a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Park National Corp OH Grows Holdings in Allergan PLC. (AGN)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://ledgergazette.com

A number of other institutional investors have also added to or reduced their stakes in AGN. Veritas Asset Management LLP acquired a new stake in Allergan PLC. during the 1st quarter worth approximately $761,339,000. Iridian Asset Management LLC CT increased its position in shares of Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after purchasing an additional 751,848 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Allergan PLC. in the 1st quarter valued at approximately $124,255,000. Vanguard Group Inc. increased its position in shares of Allergan PLC. by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after purchasing an additional 482,220 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. increased its position in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after purchasing an additional 370,400 shares during the last quarter. Institutional investors own 81.94% of the company’s stock.

A number of brokerages have commented on AGN. Royal Bank Of Canada reissued an “outperform” rating and issued a $250.00 price objective (down from $277.00) on shares of Allergan PLC. in a research report on Thursday. They noted that the move was a valuation call. Vetr raised shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research report on Monday, June 26th. BidaskClub downgraded shares of Allergan PLC. from a “sell” rating to a “strong sell” rating in a research report on Friday, August 25th. Mizuho reissued a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a research report on Monday, September 25th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $258.00 price objective on shares of Allergan PLC. in a research report on Wednesday. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $252.39.

Shares of Allergan PLC. (NYSE:AGN) traded down 0.52% during mid-day trading on Friday, reaching $188.28. 4,755,555 shares of the company were exchanged. Allergan PLC. has a 12 month low of $182.80 and a 12 month high of $256.80. The company’s 50-day moving average is $211.30 and its 200 day moving average is $230.36. The firm has a market capitalization of $62.94 billion, a price-to-earnings ratio of 5.74 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the firm earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Analysts predict that Allergan PLC. will post $16.21 EPS for the current year.

Allergan PLC. announced that its board has authorized a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Park National Corp OH Grows Holdings in Allergan PLC. (AGN)” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://ledgergazette.com/2017/10/21/park-national-corp-oh-grows-holdings-in-allergan-plc-agn.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply